Egg protein formulations and methods of manufacture thereof
The present technology relates generally to formulations comprising egg white protein, methods of manufacturing egg protein formulations and uses for egg protein formulations. In particular, several embodiments are directed to egg protein formulations for oral administration in immunotherapy of subjects affected by egg allergies.
1. A method of treating of an egg allergy by oral immunotherapy, the method comprising administering a composition comprising dried egg white protein powder comprising egg white protein to an allergic individual having the egg allergy, wherein the composition comprises:
a) about 0.1 wt. % to 90 wt. % of the egg white protein;
b) about 40-90 wt. % of one or more diluent;
c) about 1-30 wt. % of one or more filling agent;
d) about 0.01-10 wt. % of one or more lubricant and/or glidant; and
e) a capsule shell or sachet.
2. The method of claim 1 , wherein a level of the egg white protein in the egg white protein powder is stable in the composition for about 3, 6, 9, 11 or 36 months.
3. The method of claim 1 , wherein a concentration of one or more of ovomucoid, ovalbumin, and lysozyme proteins are stable for about 3, 6, 9, or 11 or 36 months in the composition.
4. The method of claim 1 , wherein the egg white protein is about 0.1 wt. % to about 21 wt. % of the composition.
5. The method of claim 1 , wherein the egg white protein is about 0.1% of the composition.
6. The method of claim 1 , wherein the composition is housed by a capsule or sachet, and the capsule or sachet comprises an amount of the composition comprising about 0.2 mg to about 1000 mg of the egg white protein in the capsule or sachet.
7. The method of claim 1 , wherein the composition is administered to the allergic individual in an amount comprising about 0.2 mg of the egg white protein.
8. The method of claim 1 , wherein the composition is administered to the allergic individual in an amount comprising about 1.0 mg of the egg white protein.
9. The method of claim 1 , wherein the composition is administered to the allergic individual in an amount comprising about 10.0 mg of the egg white protein.
10. The method of claim 1 , wherein the composition is administered to the allergic individual in an amount comprising about 100.0 mg of the egg white protein.
11. The method of claim 1 , wherein the composition is administered to the allergic individual in an amount comprising about 200.0 mg of the egg white protein.
12. The method of claim 1 , wherein the composition is administered to the allergic individual in an amount comprising about 1000.0 mg of the egg white protein.
13. The method of claim 1 , wherein the administration comprises administering the composition according to an initial day escalation.
14. The method of claim 13 , wherein the initial day escalation comprises administering 1, 2, 3, 4 or 5 doses of the composition on day 1 of treatment.
15. The method of claim 14 , wherein the doses comprise about 0.2 mg to about 3.0 mg of egg white protein.
16. The method of claim 1 , wherein the administration comprises administering the composition according to an escalation dose schedule.
17. The method of claim 16 , wherein the escalation dose schedule comprises administering one or more different doses of the composition.
18. The method of claim 17 , wherein each dose of the one or more different doses is administered daily in 2 week intervals.
19. The method of claim 17 , wherein the one or more different doses comprise 12 mg, 20 mg, 40 mg, 80 mg, 120 mg, 160 mg, 200 mg, 240 mg, 360 mg, 440 mg, 500 mg, 700 mg, 1000 mg, 1200 mg, 1500 mg, 1800 mg, or 2000 mg egg white protein.
20. The method of claim 1 , wherein the administration comprises administering the composition according to a maintenance period.